Palatin reports positive initial Phase 3 data for PL9643 dry eye drug at ARVO

PALATIN TECHNOLOGIES INC

PL9643 showed statistically significant improvement on multiple sign and symptom endpoints in Phase 2 and Phase 3 lead-in data.
No ocular adverse events or discontinuations due to tolerability; excellent safety profile.
MELODY-1 Phase 3 study continues; topline data expected in second half of 2023.
Data presented at ARVO 2023; magnitude of difference vs vehicle exceeds reported for approved products for several endpoints.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.